DEPDC7 inhibits cell proliferation, migration and invasion in hepatoma cells

Liao,Zhijun; Wang,Xinrui; Wang,Xiaojiang; Li,Lisheng; Lin,Dexin

doi:10.3892/ol.2017.7128

DEPDC7 inhibits cell proliferation, migration and invasion in hepatoma cells

Authors:
- Zhijun Liao
- Xinrui Wang
- Xiaojiang Wang
- Lisheng Li
- Dexin Lin
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350122, P.R. China
Published online on: October 3, 2017 https://doi.org/10.3892/ol.2017.7128
Pages: 7332-7338
Copyright: © Liao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DEP Domain Containing 7 (DEPDC7) is highly and specifically expressed in normal liver tissue, belonging to the class of genes of liver‑selective cell communication. Although the function of DEPDC7 remains poorly understood, its expression is decreased in liver cancer compared with normal liver tissues. It has previously been demonstrated that knockdown of DEPDC7 promotes cell growth, S phase entry and cell mobility and invasion in HepG2 cells. In the present study, it was shown that DEPDC7 expression is downregulated in four hepatoma cell lines (SMMC‑7721, Huh‑7, SK‑Hep‑1 and HepG2) and 48 hepatoma tissues, determined using western blot and immunohistochemical analysis. When DEPDC7 is overexpressed in hepatoma cell lines (SK‑Hep‑1 and Huh‑7), it inhibits cell proliferation and cell growth; inhibits cell cycle entry; and inhibits cell motility and invasion. These results, together with the results of knockdown experiments, demonstrate that DEPDC7 may have an important role in hepatoma cells growth and metastasis and suggest it could be a therapeutic target; however, in vitro studies are required to validate this hypothesis.

View Figures

View References

1	Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K and Kumada H: Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 57:1138–1147. 2017. View Article : Google Scholar : PubMed/NCBI
2	Zhang Q, Zhao S, Pang X and Chi B: MicroRNA-381 suppresses cell growth and invasion by targeting the liver receptor homolog-1 in hepatocellular carcinoma. Oncol Rep. 35:1831–1840. 2016. View Article : Google Scholar : PubMed/NCBI
3	Simoneau E, Hassanain M, Madkhali A, Salman A, Nudo CG, Chaudhury P and Metrakos P: (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol. 21:e551–e556. 2014. View Article : Google Scholar : PubMed/NCBI
4	Patel A and Sun W: Molecular targeted therapy in hepatocellular carcinoma: From biology to clinical practice and future. Curr Treat Options Oncol. 15:380–394. 2014. View Article : Google Scholar : PubMed/NCBI
5	Chappell G, Kutanzi K, Uehara T, Tryndyak V, Hong HH, Hoenerhoff M, Beland FA, Rusyn I and Pogribny IP: Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. Int J Cancer. 134:2778–2788. 2014. View Article : Google Scholar : PubMed/NCBI
6	Martincorena I and Campbell PJ: Somatic mutation in cancer and normal cells. Science. 349:1483–1489. 2015. View Article : Google Scholar : PubMed/NCBI
7	Gawin B, Niederfuhr A, Schumacher N, Hummerich H, Little PF and Gessler M: A 7.5 Mb sequence-ready PAC contig and gene expression map of human chromosome 11p13-p14.1. Genome Res. 9:1074–1086. 1999. View Article : Google Scholar : PubMed/NCBI
8	Xu W and He X: DEEP insights through the DEP domain. Structure. 18:1223–1225. 2010. View Article : Google Scholar : PubMed/NCBI
9	Consonni SV, Maurice MM and Bos JL: DEP domains: Structurally similar but functionally different. Nat Rev Mol Cell Biol. 15:357–362. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tauriello DV, Jordens I, Kirchner K, Slootstra JW, Kruitwagen T, Bouwman BA, Noutsou M, Rudiger SG, Schwamborn K, Schambony A, et al: Wnt/beta-catenin signaling requires interaction of the dishevelled DEP domain and C terminus with a discontinuous motif in frizzled. Proc Natl Acad Sci USA. 109:pp. E812–E820. 2012, View Article : Google Scholar : PubMed/NCBI
11	Wang XR, Yang H and Liao ZJ: Structure and function of the DEP domain. Chemistry of Life. 35:264–271. 2015.
12	Liao ZJ, Ma WL, Liang S, Meng W, Shang T and Zheng WL: Transcriptional regulation of genes involved in liver-selective cell communication. Nan Fang Yi Ke Da Xue Xue Bao. 28:1582–1585. 2008.PubMed/NCBI
13	Kahng YS, Lee YS, Kim BK, Park WS, Lee JY and Kang CS: Loss of heterozygosity of chromosome 8p and 11p in the dysplastic nodule and hepatocellular carcinoma. J Gastroenterol Hepatol. 18:430–436. 2003. View Article : Google Scholar : PubMed/NCBI
14	Li L, Chen W, Liang Y, Ma H, Li W, Zhou Z, Li J, Ding Y, Ren J, Lin J, et al: The Gbetagamma-Src signaling pathway regulates TNF-induced necroptosis via control of necrosome translocation. Cell Res. 24:417–432. 2014. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Meng QC, Wang HC, Song ZL, Shan ZZ, Yuan Z, Zheng Q and Huang XY: Overexpression of NDC80 is correlated with prognosis of pancreatic cancer and regulates cell proliferation. Am J Cancer Res. 5:1730–1740. 2015.PubMed/NCBI
17	Dai J, Wu W, Zhou J, Gao K, Hu G, Lin C, Zhang Y and Li X: Effect of antisense microRNA targeting survivin on rectal cancer HRC-9698 cells and its mechanism. Int J Clin Exp Pathol. 8:6057–6063. 2015.PubMed/NCBI
18	Su H, Ma C, Liu J, Li N, Gao M, Huang A, Wang X, Huang W and Huang X: Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol. 303:G1245–G1253. 2012. View Article : Google Scholar : PubMed/NCBI
19	Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, et al: Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 45:938–947. 2007. View Article : Google Scholar : PubMed/NCBI
20	Liao ZJ, Wang XR, Yang H and Zeng YT: Effects of shRNA-mediated knockdown of DEPDC7 on proliferation, migration and invasion of human hepatoma cell HepG2. Chin J Cell Biol. 37:977–983. 2015.
21	Lopez-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI